AB-107 is under clinical development by Jupiter Wellness and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AB-107’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AB-107 is under development for the treatment of psoriasis. It is administered through topical route.
Jupiter Wellness overview
Jupiter Wellness a company operates as a pharmaceutical company and the company manufactures products for physical and mental benefits. It is headquartered in Jupiter, Florida, the US.
For a complete picture of AB-107’s drug-specific PTSR and LoA scores, buy the report here.